▼ -16.96% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is $4.80, with a high forecast of $10.00 and a low forecast of $0.70. The average price target represents a -16.96% upside from the last price of $5.78.
The current consensus among 4 investment analysts is to buy stock in Ocugen.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.